interferon-alpha/IFNA5 Proteins, Antibodies, cDNA Clones, ELISA Kits Research Reagents

All interferon-alpha/IFNA5 reagents are produced in house and quality controlled, including 9 interferon-alpha/IFNA5 Antibody, 2 interferon-alpha/IFNA5 ELISA, 39 interferon-alpha/IFNA5 Gene, 2 interferon-alpha/IFNA5 IP Kit, 5 interferon-alpha/IFNA5 Lysate, 8 interferon-alpha/IFNA5 Protein, 2 interferon-alpha/IFNA5 qPCR. All interferon-alpha/IFNA5 reagents are ready to use.

All interferon-alpha/IFNA5 Reagents

interferon-alpha/IFNA5 Protein (8)

    interferon-alpha/IFNA5 Antibody (9)

      interferon-alpha/IFNA5 ELISA 试剂盒(即用型)& ELISA 抗体对套装(非即用型)(2)

      interferon-alpha/IFNA5 cDNA Clone (39)

      NM_002169.1

      克隆载体 cDNA 产品

      In lentiviral vector

      NM_010505.2

      克隆载体 cDNA 产品

      In lentiviral vector

      XM_001076062.1

      克隆载体 cDNA 产品

      In lentiviral vector

      interferon-alpha/IFNA5 Lysate (5)

        interferon-alpha/IFNA5 分子背景

        Interferon, alpha 5 (IFNA5) belongs to the alpha/beta interferon family. IFNA5 is the only IFNA subtype detected in normal liver, while a mixture of subtypes is observed in the liver tissue of patients with chronic hepatitis C. Interferons are produced by macrophages, IFN-alpha have antiviral activities. Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase. IFN-alpha, the first cytokine to be produced by recombinant DNA technology, has emerged as an important regulator of growth and differentiation, affecting cellular communication and signal transduction pathways as well as immunological control. Originally discovered as an antiviral substance, the efficacy of IFN-alpha in malignant, viral, immunological, angiogenic, inflammatory, and fibrotic diseases suggests a spectrum of interrelated pathophysiologies. IFN-alpha emerged as a prototypic tumor suppressor protein that represses the clinical tumorigenic phenotype in some malignancies capable of differentiation.

        interferon-alpha/IFNA5 参考文献

        • Lau JY, et al. (1993) Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. Lancet. 342(8881): 1208-9.
        • Kessler DS, et al. (1990) Interferon-alpha regulates nuclear translocation and DNA-binding affinity of ISGF3, a multimeric transcriptional activator. Genes Dev. 4(10): 1753-65.
        • Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A. 91(4): 1198-205.

        Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.